| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.091 | 0.006 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.008 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.008 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.008 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.009 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.074 | 0.01 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |